Bayesian Capital Management’s ADMA Biologics ADMA Stock Holding History

Bayesian Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$430K	Buy	+47,700	New	+$753K	0.52%	64
2024 Q3	–	Sell	-15,615	Closed	-$175K	–	648
2024 Q2	$175K	Buy	+15,615	New	+$131K	0.02%	619
2024 Q1	–	Sell	-57,915	Closed	-$262K	–	754
2023 Q4	$262K	Sell	57,915 -18,185	-24%	-$67.3K	0.03%	543
2023 Q3	$272K	Buy	+76,100	New	+$293K	0.03%	491
2023 Q2	–	Sell	-11,146	Closed	-$36.9K	–	755
2023 Q1	$36.9K	Sell	11,146 -30,854	-73%	-$107K	﹤0.01%	721
2022 Q4	$163K	Buy	+42,000	New	+$130K	0.02%	622
2022 Q3	–	Sell	-55,300	Closed	-$109K	–	670
2022 Q2	$109K	Buy	+55,300	New	+$109K	0.02%	680

Other funds holding ADMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bayesian Capital Management's ADMA Position: Q1 2026 in Review

Bayesian Capital Management opened a new position in ADMA Biologics (ADMA) in Q1 2026: 47,700 shares worth $430K. The stake represents 0.52% of the portfolio and ranks #64 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in ADMA as recently as Q2 2024.

Bayesian Capital Management first reported a position in ADMA in Q2 2022 and has held it in 7 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

Bayesian Capital Management held 47,700 shares of ADMA Biologics worth $430K as of Q1 2026.
ADMA Biologics was a new Bayesian Capital Management position in Q1 2026.
ADMA Biologics made up 0.52% of Bayesian Capital Management's portfolio in Q1 2026, its #64 holding.
Bayesian Capital Management first reported a position in ADMA Biologics in Q2 2022 and has held it in 7 quarters since.
356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.